Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management
Authors:
- Deepak VermaDVDeepak Verma
- Amena FirozAFAmena Firoz
- Sameer Krishna Prasad GarlapatiSGSameer Krishna Prasad Garlapati
- Thanmay Sai Charaan Reddy SathiTSThanmay Sai Charaan Reddy Sathi
- Muhammad HarisMHMuhammad Haris
- Bibek DhunganaBDBibek Dhungana
- Barun RayBRBarun Ray
- Gunjan ShahGSGunjan Shah
- Palak PaudelPPPalak Paudel
Open Access
- 17 August 2021
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 13 (8)
Abstract
Cardiorenal syndrome refers to combined cardiac and renal dysfunction that adversely impacts both organs and is also associated with severe clinical outcomes. The pathophysiology is believed to be multifactorial and complex. Increased central venous pressure and intra-abdominal pressure, overactivation of the Renin-Angiotensin-Aldosterone System (RAAS), systemic illnesses like sepsis, amyloidosis, diabetes are important factors in developing the cardiorenal syndrome. Our review article attempts to review the pathophysiology and treatment aspect of cardiorenal syndrome and explores potential therapeutic strategies that can be adopted for the management. We searched PubMed, EMBASE, Google Scholar for relevant articles using different keywords and Medical Subject Headings, and finalized 38 articles to be included in our study. Cardiorenal syndrome management aims to eliminate venous congestion and fluid retention, which leads to improved cardiorenal status. This is usually achieved using pharmacologic agents like diuretics, vasodilators, inotropes, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs), neprilysin inhibitors, and extracorporeal methods like ultrafiltration. The use of therapeutic agents such as sodium-glucose co-transporter 2 inhibitors and tolvaptan (a vasopressin V2 receptor antagonist), and cardiac resynchronization therapy has also been shown to have potential benefits in managing the disease. These agents can be instrumental in the management and require large-scale clinical trials specifically aimed at improving cardiorenal outcomes based on severity and type of cardiorenal syndrome.Keywords
This publication has 38 references indexed in Scilit:
- Cardiorenal Syndrome and the Role of Ultrafiltration in Heart FailureCurrent Heart Failure Reports, 2013
- Diuretic Strategies in Patients with Acute Decompensated Heart FailureNew England Journal of Medicine, 2011
- Cardiac Resynchronization Therapy in the Cardiorenal SyndromeInternational Journal of Nephrology, 2011
- Renal function and mortality following cardiac resynchronization therapyEuropean Heart Journal, 2010
- Potential Effects of Aggressive Decongestion During the Treatment of Decompensated Heart Failure on Renal Function and SurvivalCirculation, 2010
- V2receptor antagonism with tolvaptan in heart failureExpert Opinion on Investigational Drugs, 2007
- In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive MedicationsJACC, 2005
- Sustained Sympathoinhibitory Effects of Cardiac Resynchronization Therapy in Severe Heart FailureHypertension, 2004
- Renal Insufficiency and Heart FailureCirculation, 2004
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999